Trial Profile

A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 08 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bimekizumab (Primary) ; Risankizumab (Primary)
Indications Psoriatic arthritis
Focus Registrational; Therapeutic Use
Acronyms BE BOLD
Sponsors UCB Biopharma

Most Recent Events

30 Jul 2026 According to a UCB pharmaceutical media release, the data from the trial were presented at EULAR 2026 annual meeting In June 2026.
06 Jul 2026 Status changed from active, no longer recruiting to completed.
19 May 2026 According to a UCB pharmaceutical media release, the data from the trial will presented at EULAR 2026 annual meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com